Compare Dow Inc (DOW) vs Eli Lilly And Co (LLY) Price & Performance

DOW trades at $30.78, up 0.65% today, with a bullish technical signal and positive earnings beats in recent quarters. However, the company reported a net loss of $2.62 billion in 2025, with declining revenue and negative profit margins. Analyst consensus is a 'Hold' with a $35.11 price target, suggesting modest upside potential from current levels.

The outlook is mixed; earnings improvements and dividend payments provide support, but persistent losses and high debt pose risks. Investment opportunity hinges on a turnaround in profitability, while key risks include competitive pressures and macroeconomic headwinds affecting the chemicals sector.

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.